A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD.
about
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseasePhosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseaseA rational approach to single, dual and triple therapy in COPDPharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma.The in vivo efficacy and side effect pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long-acting β 2-adrenoceptor agonist in preclinical animal species.Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.Functional respiratory imaging to assess the interaction between systemic roflumilast and inhaled ICS/LABA/LAMARecent advances in pre-clinical mouse models of COPD.PDE4 inhibitors: a review of current developments (2005 - 2009).Current perspectives of oxidative stress and its measurement in chronic obstructive pulmonary disease.Metabolite identification by mass spectrometry: forty years of evolution.Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management.PDE4: a novel target in the treatment of chronic obstructive pulmonary disease.Emerging drugs for chronic obstructive pulmonary disease.Phosphodiesterase-4 inhibitor therapy for lung diseases.Efficacy and safety of high-dose ciclesonide for the treatment of severe asthma.New anti-inflammatory targets for chronic obstructive pulmonary disease.Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases.Longitudinal FEV1 dose-response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease.Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
P2860
Q24202545-CB140960-B98E-4895-842F-6CB2E90F3B6BQ24234493-D93773B9-B814-4415-9855-DF713EA05DDAQ26776477-0A5C06FF-F649-46DC-9873-53C20A632C53Q26777927-A2DD9367-E7B7-4003-86E3-0C917149A207Q33737175-99A0C46C-9C9B-4474-BB3C-D2F1EF8A806FQ34292566-6E2A91C3-9CF3-48E3-A22F-5E86F49BDF1FQ35377816-D598528D-94D1-4D1D-8B9E-81FEE6CBAE6EQ36443665-962FF973-7EA1-4E5E-92E9-F7271CB7DE7BQ36557694-E9061D78-B86C-4719-9C5C-168D0EBA1D5EQ37426720-B62C4515-EAA5-4E85-BB3A-06C9B7B6676DQ37615398-FCF73748-5CB4-43F8-9692-8EF6C1EF8C3BQ37776727-A2C430DB-F2D6-4847-B66A-B8BA23325DABQ37857237-CC92D7CD-A7AC-47B2-9B49-A8228921E3F4Q37880077-B7C2BE66-7F7F-4237-9CB9-8BD8110CB3E8Q37963175-1A39CBD3-2941-4D56-A4C7-724FA9398EF5Q37984088-20DA7402-C83B-4EB4-8B8F-4EA7FEC2AB77Q38105165-32C2F25C-B82E-4D6B-835A-9D085A405422Q38130512-E820B9ED-2DE6-435D-8FC9-2B5F552BD8E9Q38131512-0B4EAACD-4B50-48DB-8DB7-F8BCFDFAA192Q38187182-56AA54D3-5E14-44D0-8A0E-6F7A9C2F8DCAQ38258537-B1449925-6FAA-400C-BCAE-BF315397D307Q38681962-9093D8F7-CC29-4257-84C6-9104384E97FDQ39548676-EB823F2F-4751-4CF5-9349-6A1C3BA69315Q47551310-0087F69A-C791-48C1-B1BD-A5A39E57668E
P2860
A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
A controlled trial of 6-weeks' ...... rase type-4 inhibitor in COPD.
@en
A controlled trial of 6-weeks' ...... rase type-4 inhibitor in COPD.
@nl
type
label
A controlled trial of 6-weeks' ...... rase type-4 inhibitor in COPD.
@en
A controlled trial of 6-weeks' ...... rase type-4 inhibitor in COPD.
@nl
prefLabel
A controlled trial of 6-weeks' ...... rase type-4 inhibitor in COPD.
@en
A controlled trial of 6-weeks' ...... rase type-4 inhibitor in COPD.
@nl
P2093
P1476
A controlled trial of 6-weeks' ...... rase type-4 inhibitor in COPD.
@en
P2093
G Atkinson
UK-500,001 Global Study Team
P304
P356
10.1183/09031936.00068908
P577
2009-02-12T00:00:00Z